Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 15, 2008

View Archived Issues

Clinical data on elotuzumab in multiple myeloma emerging

Antineoplastons induce responses in anaplastic astrocytoma patients

Synergy successfully completes phase I trial of SP-304 in healthy subjects

ITI presents development update of ITI-111 for acute repetitive seizure in epilepsy

Novel agents for treating HCV infection jointly disclosed by Array and InterMune

Novavax reports preclinical results from study of RSV vaccine in mice

Wyeth initiates phase I study of Ablynx Nanobody targeting TNF-alpha

Cytos initiates phase IIb clinical study of CYT003-QbG10 for allergy and asthma

Futura reports results from phase I study of PET-500 for premature ejaculation

Neogenix to initiate clinical trial of monoclonal antibodies for colorectal and pancreatic cancer

Javelin reports results from phase III efficacy study of Dyloject in postsurgical pain

Clinical results disclosed for a novel inhibitor of sodium and calcium channels in epilepsy

Arana commences international phase II trial of ART-621 in rheumatoid arthritis

Calcineurin inhibition can guide dosing of voclosporin in plaque psoriasis patients

InterMune to report triple combination ITMN-191 study results in January

CBP-501 enters phase II trials for malignant pleural mesothelioma

Halozyme starts dosing in phase I trial of bisphosphonate plus rHuPH20 enzyme

KAI-1678 enters phase IIa trials for the treatment of pain

Palatin and AstraZeneca extend research collaboration and license agreement

Alexza reports positive results from phase III clinical trial of AZ-004 in bipolar disorder

Almirall reports positive results from phase IIa study of LAS-100977 in asthma

Novel Pan-PI3 kinase inhibitor identified for leukemia and myeloma

Recent patents describe new treatment options for endocrine-associated disorders

Recent patents disclose new treatments for obesity

FDA approves Lusedra for sedation in diagnostic or therapeutic procedures

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...